AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:28 13/06/2025 BST			5-day change	1st Jan Change
10,986.00 ^GBX	-0.40%		+1.89%	+4.95%

06-02	ASTRAZENECA : Buy rating from JP Morgan	ZD
06-02	UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	RE

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

Published on 25/04/2024 at 16:20, updated on 25/04/2024 at 17:02

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about AstraZeneca PLC

ASTRAZENECA : Buy rating from JP Morgan	06-02	ZD
UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	06-02	RE
UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	06-02	RE
Global markets live: Tesla, Sanofi, Apple, JPMorgan, Microsoft…	06-02
AstraZeneca says Enhertu slashes disease progression risk in cancer	06-02	AN
AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer	06-02	MT
AstraZeneca, Daiichi Sankyo's Gastric Cancer Phase 3 Trial Shows 'Statistically Significant' Improvement in Overall Survival	06-02	MT
Hutchmed reports progress in late-stage lung cancer trial	06-02	AN
AstraZeneca: promising results for Imfinzi in gastric cancer	06-02	CF
AstraZeneca Says Imfinzi Combo Boosts Event-Free Survival in Gastric Cancer Trial	06-02	MT
AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial	06-02	MT
AstraZeneca: camizestrant effective in breast cancer	06-02	CF
ASTRAZENECA : Receives a Buy rating from JP Morgan	06-02	ZD
Stocks edge down as renewed trade tensions continue	06-02	AN
AstraZeneca hails Imfinzi results on early stage gastric cancer	06-02	AN
AstraZeneca's Breast Cancer Treatment Extends Progression-free Survival in Late-stage Trial	06-02	MT
AstraZeneca Reports Positive Phase 3 Data for Imfinzi Regimen for Early-stage Gastric Cancer	06-02	MT
PRESS DIGEST- Financial Times - June 2	06-02	RE
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk	06-01	RE
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk	06-01	RE
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial	06-01	RE
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression	05-31	RE
FTSE 100 rises despite tariff worries; M&G shines	05-30	AN
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools	05-30	MT
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy	05-30	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

06-18 - J.P. Morgan European Healthcare Forum

More about the company